Background Diabetic Retinopathy

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Background Diabetic Retinopathy

MalaCards integrated aliases for Background Diabetic Retinopathy:

Name: Background Diabetic Retinopathy 12 14
Non Proliferative Diabetic Retinopathy 12
Non-Proliferative Diabetic Retinopathy 12
Nonproliferative Diabetic Retinopathy 69


External Ids:

Disease Ontology 12 DOID:13208
ICD9CM 35 362.01 362.03
UMLS 69 C0004606

Summaries for Background Diabetic Retinopathy

MalaCards based summary : Background Diabetic Retinopathy, also known as non proliferative diabetic retinopathy, is related to microvascular complications of diabetes 1 and severe nonproliferative diabetic retinopathy. An important gene associated with Background Diabetic Retinopathy is TLR9 (Toll Like Receptor 9), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Malaria. The drugs Hydroxocobalamin and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and testes, and related phenotypes are cellular and digestive/alimentary

Related Diseases for Background Diabetic Retinopathy

Diseases related to Background Diabetic Retinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
id Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 11.2
2 severe nonproliferative diabetic retinopathy 11.2
3 metal metabolism disorder 10.6 INS VEGFA
4 tetrahydrobiopterin-responsive hyperphenylalaninemia/phenylketonuria 10.5 TLR9 VEGFA
5 cutaneous leishmaniasis 10.5 ANGPT2 VEGFA
6 pyruvate kinase deficiency, muscle type 10.5 ANGPT2 VEGFA
7 bipolar i disorder 10.5 ANGPT2 VEGFA
8 lipoic acid synthetase deficiency 10.5 ANGPT2 VEGFA
9 retinitis pigmentosa 70 10.4 ALB VEGFA
10 malignant granular cell skin tumor 10.4 ANGPT2 VEGFA
11 pylorus cancer 10.4 ALB VEGFA
12 cataract 10.4 ALB INS
13 common cold 10.4 ALB TLR9
14 tonsil cancer 10.4 ALB INS
15 autoimmune disease of cardiovascular system 10.4 ALB TLR9
16 conjunctival vascular disease 10.3 ALB INS
17 bardet-biedl syndrome 17 10.3 ALB VEGFA
18 retinitis pigmentosa 17 10.3 ALB INS
19 spondylolysis 10.3 INS TLR9 VEGFA
20 late yaws 10.3 ALB TLR9
21 diabetes mellitus, insulin-dependent, 3 10.3 ANGPT2 VEGFA
22 hyperlipoproteinemia type iv 10.3 ALB INS
23 mikulicz disease 10.3 ALB TLR9
24 chronic gonococcal salpingitis 10.3 ALB ANGPT2
25 esophageal leukoplakia 10.3 ALB VEGFA
26 renal fibrosis 10.2 ANGPT2 VEGFA
27 ischemic heart disease 10.2 ALB VEGFA
28 dentin caries 10.2 ALB TLR9
29 benign mammary dysplasia 10.2 ALB TLR9
30 hidradenoma 10.1 ANGPT2 VEGFA
31 gallbladder cancer 10.1 ALB TLR9 VEGFA
32 calcinosis 10.1 ALB INS TLR9
33 tuberculum sellae meningioma 10.1 ALB INS TLR9
34 paroxysmal nonkinesigenic dyskinesia 2 10.1 HBA2 INS
35 neuropathy, hereditary sensory and autonomic, type ic 10.1 HBA2 INS
36 peripheral artery disease 10.1 ALB INS VEGFA
37 tinf2-related dyskeratosis congenita 10.0 HBA2 INS
38 gastric ulcer 10.0 ALB TLR9
39 exophthalmic ophthalmoplegia 10.0 ALB VEGFA
40 congenital heart defects, nonsyndromic, 2 10.0 HBA2 INS
41 ovarian hyperstimulation syndrome 9.9 ALB VEGFA
42 breast fibroadenoma 9.8 HBA2 INS VEGFA
43 prostate carcinoma in situ 9.8 ALB INS TLR9 VEGFA
44 algoneurodystrophy 9.8 HBA2 INS VEGFA
45 neuropathy, hereditary sensory and autonomic, type vi 9.8 ANGPT2 VEGFA
46 retinitis 9.7
47 endotheliitis 9.7
48 citrullinemia, adult-onset type ii 9.7 ALB ANGPT2 INS VEGFA
49 hemopericardium 9.6 ALB HBA2 INS
50 hypertrichosis 9.3 ALB HBA2 INS TLR9

Graphical network of the top 20 diseases related to Background Diabetic Retinopathy:

Diseases related to Background Diabetic Retinopathy

Symptoms & Phenotypes for Background Diabetic Retinopathy

MGI Mouse Phenotypes related to Background Diabetic Retinopathy:

id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.5 ALB ANGPT2 CHN2 INS NAGPA TLR9
2 digestive/alimentary MP:0005381 9.02 ALB ANGPT2 INS TLR9 VEGFA

Drugs & Therapeutics for Background Diabetic Retinopathy

Drugs for Background Diabetic Retinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 105)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 216974-75-3
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1 347396-82-1 459903
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 1,Phase 2 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Glucosamine Approved, Nutraceutical Phase 4,Phase 2 3416-24-8 439213
10 Hematinics Phase 4
11 Micronutrients Phase 4,Phase 2,Phase 1
12 Trace Elements Phase 4,Phase 2,Phase 1
13 Vitamin B 12 Phase 4
14 Vitamin B 6 Phase 4
15 Vitamin B Complex Phase 4,Phase 1,Phase 2
16 Vitamins Phase 4,Phase 2,Phase 1
17 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
18 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
19 Hypoglycemic Agents Phase 4,Phase 2
20 Anticoagulants Phase 4,Phase 2
21 Antimetabolites Phase 4,Phase 2
22 Fibrinolytic Agents Phase 4,Phase 2
23 Glucuronyl glucosamine glycan sulfate Phase 4,Phase 2
24 Hypolipidemic Agents Phase 4,Phase 2
25 Lipid Regulating Agents Phase 4,Phase 2
26 insulin Phase 4
27 Insulin, Globin Zinc Phase 4
Cobalamin Nutraceutical Phase 4 13408-78-1 6438156
29 Folate Nutraceutical Phase 4,Phase 1,Phase 2
Methylcobalamin Experimental, Nutraceutical Phase 4 13422-55-4
31 Vitamin B12 Nutraceutical Phase 4
32 Vitamin B9 Nutraceutical Phase 4,Phase 1,Phase 2
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
Nepafenac Approved Phase 3 78281-72-8 151075
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
Ruboxistaurin Investigational Phase 3 202260-21-7, 169939-94-0 153999
39 Analgesics Phase 3
40 Analgesics, Non-Narcotic Phase 3
41 Antiemetics Phase 3,Phase 2
42 Anti-Inflammatory Agents Phase 3,Phase 2
43 Anti-Inflammatory Agents, Non-Steroidal Phase 3
44 Antineoplastic Agents, Hormonal Phase 3,Phase 2
45 Antirheumatic Agents Phase 3
46 Autonomic Agents Phase 3,Phase 2
47 Gastrointestinal Agents Phase 3,Phase 2
48 glucocorticoids Phase 3,Phase 2
49 Hormone Antagonists Phase 3,Phase 2
50 Hormones Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 62)

id Name Status NCT ID Phase Drugs
1 Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy Unknown status NCT01921192 Phase 4 Folic Acid, vit B6 and B12;Placebo
2 Changes in Electroretinogram and Contrast Sensitivity After PASCAL Treatment Unknown status NCT00563043 Phase 4
3 Changes in Macular Thickness After Patterns Scan Laser Unknown status NCT00563628 Phase 4
4 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
5 Avastin for Post-Photocoagulation Macular Edema Completed NCT00801866 Phase 4 Bevacizumab
6 CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea Recruiting NCT02874313 Phase 4 Pharmacological treatment
7 Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap Recruiting NCT02521116 Phase 4
8 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Not yet recruiting NCT02834663 Phase 4 Lucentis
9 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Unknown status NCT00908778 Phase 3 Vitreosolve;Vitreosolve
10 Nepafenac Once Daily for Macular Edema - Study 2 Completed NCT01872611 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
11 Nepafenac Once Daily for Macular Edema - Study 1 Completed NCT01853072 Phase 3 Nepafenac Ophthalmic Suspension, 0.3%;Prednisolone acetate
12 Intravitreal Bevacizumab for Diabetic Retinopathy Completed NCT00600262 Phase 2, Phase 3 intravitreal bevacizumab
13 Reduction in the Occurrence of Center-Involved Diabetic Macular Edema Completed NCT00090519 Phase 3 ruboxistaurin;placebo
14 Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema Completed NCT00444600 Phase 3 Triamcinolone Acetonide + laser;Ranibizumab + laser;Sham injection + laser;Ranibizumab + deferred laser
15 Anti-VEGF Treatment for Prevention of PDR/DME Recruiting NCT02634333 Phase 3 Prompt aflibercept;Deferred aflibercept
16 Treatment for CI-DME in Eyes With Very Good VA Study Recruiting NCT01909791 Phase 3 Prompt aflibercept;Deferred aflibercept
17 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) Active, not recruiting NCT02718326 Phase 3 Intravitreal aflibercept injection [IAI];Sham
18 Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Active, not recruiting NCT02388984 Phase 3 Compound danshen dripping pills;Placebo
19 Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248131 Phase 3 Octreotide acetate in microspheres
20 Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy Terminated NCT00248157 Phase 3 Octreotide acetate in microspheres
21 A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects Terminated NCT00664183 Phase 2, Phase 3 Vitreosolve
22 A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Unknown status NCT02435862 Phase 2 1.0mg Luminate®;2.0mg Luminate®;3.0mg Luminate®
23 Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Completed NCT02062034 Phase 2 Ubiquinone;Combined antioxidant therapy;Placebo
24 Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy Completed NCT00917553 Phase 2 doxycycline monohydrate;Placebo
25 Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment Completed NCT00198471 Phase 2 Vitrase
26 Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Completed NCT01571232 Phase 2 dexamethasone intravitreal implant;intravitreal bevacizumab
27 Diabetic Retinopathy Sulodexide Study Completed NCT01295775 Phase 2 sulodexide
28 Ranibizumab and Bevacizumab for Diabetic Macular Edema Completed NCT01610557 Phase 2 Ranibizumab;Bevacizumab
29 The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) Recruiting NCT03197870 Phase 2 AKB-9778;Placebo
30 A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR Recruiting NCT02681809 Phase 2 ocriplasmin 0.0625mg;ocriplasmin 0.125mg;Sham injection
31 A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated. Recruiting NCT03238963 Phase 2 BI 1467335;Placebo
32 The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy Recruiting NCT03006081 Phase 2 Intravitreal Aflibercept injection
33 Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE) Active, not recruiting NCT01552408 Phase 1, Phase 2 0.3 mg ranibizumab
34 A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy Not yet recruiting NCT03258242 Phase 2 Keluo Xin capsule;Placebo oral capsule
35 The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy Suspended NCT01880372 Phase 1, Phase 2
36 Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy Unknown status NCT02309502
37 Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus Unknown status NCT01107132
38 Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography Unknown status NCT01790945
39 OCT Biomarkers for Diabetic Retinopathy Unknown status NCT02330042
40 Study on Tear Proteins in Diabetic Retinopathy of Type 2 Diabetics Unknown status NCT00698698
41 Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER) Completed NCT01440660
42 Validation of a Predictive Model to Estimate the Risk of Conversion to Clinically Significant Macular Edema and/or Vision Loss in Mild Nonproliferative Diabetic Retinopathy in Diabetes Type 2 Completed NCT00763802
43 Identifying Progression of Retinal Disease in Eyes With NPDR in Diabetes Type 2 Using Non-invasive Procedures Completed NCT01145599
44 Computer Detection of Diabetic Retinopathy Compared to Clinical Examination Completed NCT01625598
45 Diabetes Visual Function Supplement Study Completed NCT01646047
46 Observational Study of DME Following Scatter Laser Photocoagulation Completed NCT00687154
47 Neurovascular Coupling in Patients With Early Stage Diabetes Retinopathy Completed NCT00712842
48 Evaluation of Blood-retinal Barrier Functional Alterations by Optical Coherence Tomography Completed NCT01220804
49 Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study Completed NCT01915238
50 Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR Recruiting NCT01759121

Search NIH Clinical Center for Background Diabetic Retinopathy

Genetic Tests for Background Diabetic Retinopathy

Anatomical Context for Background Diabetic Retinopathy

MalaCards organs/tissues related to Background Diabetic Retinopathy:

Eye, Endothelial, Testes, Kidney

Publications for Background Diabetic Retinopathy

Articles related to Background Diabetic Retinopathy:

(show all 11)
id Title Authors Year
The influence of background diabetic retinopathy in the second eye on rates of progression of diabetic retinopathy between 2005 and 2010. ( 23551550 )
Massive subretinal bleed in a patient with background diabetic retinopathy and on treatment with warfarin. ( 12855977 )
From minimal background diabetic retinopathy to profuse sight threatening vitreoretinal haemorrhage: management issues in a case of pregestational diabetes and pregnancy. ( 12873299 )
Background diabetic retinopathy in Harare, Zimbabwe. ( 10448253 )
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. ( 9519746 )
Contrast sensitivity changes in background diabetic retinopathy. ( 2013027 )
Does increased platelet aggregation have a prognostic value in the deterioration of background diabetic retinopathy? The Damad Study Group. ( 2270529 )
Treatment of background diabetic retinopathy. ( 3508804 )
Pattern electroretinograms become abnormal when background diabetic retinopathy deteriorates to a preproliferative stage: possible use as a screening test. ( 3964635 )
Blood pressure and the progression of mild background diabetic retinopathy. ( 4077241 )
Effect of pure O2-breathing on retinal blood flow in normals and in patients with background diabetic retinopathy. ( 6690224 )

Variations for Background Diabetic Retinopathy

Expression for Background Diabetic Retinopathy

Search GEO for disease gene expression data for Background Diabetic Retinopathy.

Pathways for Background Diabetic Retinopathy

GO Terms for Background Diabetic Retinopathy

Cellular components related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.43 ALB ANGPT2 HBA2 INS TLR9 VEGFA
2 extracellular space GO:0005615 9.1 ALB ANGPT2 HBA2 INS TLR9 VEGFA

Biological processes related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of protein autophosphorylation GO:0031954 8.62 INS VEGFA

Molecular functions related to Background Diabetic Retinopathy according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 oxygen binding GO:0019825 8.62 ALB HBA2

Sources for Background Diabetic Retinopathy

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....